Ticker Details
Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date:	March 26, 1990
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.17B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.40%
Avg Daily Range (30 D):	$0.84 | 2.14%
Avg Daily Range (90 D):	$0.72 | 2.05%

Institutional Daily Volume
Avg Daily Volume:	1.1M
Avg Daily Volume (30 D):	.78M
Avg Daily Volume (90 D):	.75M

Trade Size
Avg Trade Size (Sh.):	153
Avg Trade Size (Sh.) (30 D):	62
Avg Trade Size (Sh.) (90 D):	61

Institutional Trades
Total Institutional Trades:	5,097
Avg Institutional Trade:	$2.2M
Avg Institutional Trade (30 D):	$2.73M
Avg Institutional Trade (90 D):	$3.35M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.05M
Avg Closing Trade (30 D):	$5M
Avg Closing Trade (90 D):	$5.75M
Avg Closing Volume:	84.57K

News

Jun 14, 2026 @ 2:21 PM Celldex Presents Long-Term Barzolvolimab Results D... Source: Na

Jun 14, 2026 @ 9:15 AM Celldex Presents Positive First-in-Human Results f... Source: Na

Apr 6, 2026 @ 2:53 PM Celldex Therapeutics Announces Closing of Public O... Source: Celldex Therapeutics, Inc.

Apr 2, 2026 @ 1:48 AM Celldex Announces Pricing of $300 Million Public O... Source: Na

Mar 1, 2026 @ 2:45 PM Celldex Presents Positive Data Demonstrating Barzo... Source: Celldex

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-4.35	$-.94	$-1.18
Diluted EPS	$-4.35	$-.94	$-1.18
Revenue	$.16M	$.02M	$.02M
Gross Profit
Net Income / Loss	$-300.55M	$-73.5M	$-78.69M
Operating Income / Loss	$-325.83M	$-80.62M	$-84.44M
Cost of Revenue
Net Cash Flow	$24.41M	$11.73M	$6.86M
PE Ratio

Splits
Feb 11, 2019	1:15
Mar 10, 2008	1:12
Mar 07, 2008	1:12